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Editors,
We read with great interest Henderson and colleagues' paper in your journal (2009; 29:165-169) , which reported that aripiprazole reduced olanzapine-induced overweight/obesity and hyperlipidemia in a 10-week placebo-controlled double-blind crossover study. This and their previous studies 1,2 provide a new way for controlling olanzapine-and clozapine-induced weight gain/obesity using another atypical 9, 10 . We suggest that aripiprazole's D2 agonistic property may account partly for the effect of aripiprazole in reducing olanzapine-induced overweight /obesity. Atypical antipsychotics such as olanzapine may increase appetite through the dopamine-mediated reward pathway 11 . Dopamine D2 agonists have been reported to reduce food intake by acting in hypothalamic areas 12 .
Another possible mechanism of aripiprazole may be via the activation of the PI3K/Akt pathway. The PI3K/Akt pathway plays an important role in cellular proliferation, growth and metabolism 13 . Over-expression of the pathway causes cancer but defects in the pathway could induce metabolic disorders. The PI3K/Akt pathway plays a key role in the action of insulin via control of Glu4, which transports glucose into the cells 14 . The activity of the PI3K/Akt pathway in insulin-mediated Glu4 activation is impaired in olanzapine-induced obesity 15 . Aripiprazole may have an effect on the activation of the PI3K/Akt pathway via its agonistic effect on D2
receptors. In fact, D2 receptor agonist (bromocriptine) has been reported to increase the PI3K/Akt pathway activity 16 . It is possible that aripiprazole can restore the impairment of the PI3K/Akt pathway in insulin-mediated Glu4 activation caused by olanzapine so that the side-effect of weight gain is reduced. Further studies on these mechanisms will improve our understanding and management of atypical antipsychotic-induced weight gain/obesity.
